Cognition, serum BDNF levels, and BDNF Val66Met polymorphism in type 2 diabetes patients and healthy controls

• Published in: Oncotarget 2018-01, Vol.9 (3), p.3653-3662
• Main Authors: Zhen, Yan-Feng, Liu, Xing-Yu, Zhou, Dong-Hao, Du, Xiangdong, Yin, Guangzhong, Zhang, Yingyang, Fang, Hui, Xu, Gang, Soares, Jair C, Zhang, Xiang Yang
• Format: Article
• Language: English
• Subjects: Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.23342

Type 2 diabetes (T2DM) is associated with cognitive deficits. However, their pathophysiological mechanisms are still unknown. Recent study suggests that brain-derived neurotrophic factor (BDNF) is correlated with cognitive deficits in T2DM patients. This study was to determine whether altered serum BDNF levels and cognitive deficits depended on the Val66Met polymorphism in T2DM. The Val66Met polymorphism may not contribute directly to the susceptibility to T2DM. The total and nearly all index scores (all < 0.01) except for the attention and visuospatial/constructional indexes (both > 0.05) of RBANS were markedly decreased in T2DM compared with healthy controls. Serum BDNF levels were significantly lower in patients than that in controls ( < 0.001), and BDNF was positively associated with delayed memory in patients ( < 0.05). The Met variant was associated with worse delayed memory performance among T2DM patients but not among normal controls. Moreover, serum BDNF was positively associated with delayed memory among Met homozygote patients ( = 0.29, = 2.21, = 0.033), while serum BDNF was negatively associated the RBANS total score ( = -0.92, = -3.40, = 0.002) and language index ( = -1.17, = -3.54, = 0.001) among Val homozygote T2DM patients. gene Val66Met variation may be associated with cognitive deficits in T2DM, especially with delayed memory. The association between lower BDNF serum levels and cognitive impairment in T2DM is dependent on the Val66Met polymorphism. We recruited 311 T2DM patients and 346 healthy controls and compared them on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), serum BDNF levels, and the Val66Met polymorphism.